Supporting the biopharma industry as it is develops and launches the most cutting edge innovation in Precision Medicine
From cell and gene therapies to antibody-drug conjugates, the biopharma industry is in an era of unprecedented innovation. However, companies must grapple with complexities around which partnerships to strike to access the data necessary to be a leader in Precision Medicine, how to navigate regional and country nuances related to areas such as reimbursement and availability of diagnostic tests, while driving organizational changes needed to be successful in this innovative field. KPMG has built a unique Precision Medicine offering which combines our proprietary Precision Medicine Insights database, our worldwide experience base, as well as our commercial launch, transaction assessment, and performance improvement offerings to transform the Precision Medicine businesses of our biopharma clients.
Biopharma deal trends outlook for 2022
Deal strategies will focus on risk mitigation, accelerated development, or risk sharing (licensing, partnerships, R&D collaborations).
Inflation Reduction Act impact on biopharma portfolio strategies
An examination of potential implications for how drug manufacturers manage their portfolios in the wake of the Inflation Reduction Act